文献速递神经肿瘤脊柱脊髓外科

脊髓膜瘤的临床与甲基化组学特征

Clinical and methylomic features of spinal meningiomas.
PubMed 文献 · J Neurooncol · 2024-09-10

本研究回顾性分析本院2010至2023年切除的脊髓膜瘤(SM)的临床与甲基化特征。65例SM(53例患者)中,5年无进展生存率为90%,次全切除与复发或进展相关(p=.017);甲基化分型可分为高甲基化、中甲基化和低甲基化亚组,高甲基化亚组与更高WHO级别(p=.046)及高风险组织学亚型(p<.001)相关。

要点

  • 脊髓膜瘤次全切除与复发或进展相关(p=.017)。
  • 高甲基化亚组与更高WHO级别(p=.046)及高风险组织学亚型(p<.001)相关。
  • 低甲基化亚组在22q染色体拷贝数缺失方面最少见(p<.0001)。

核心结论

  • 脊髓膜瘤比其颅内对应肿瘤更偏良性,全切除可获得长期无进展生存。
  • 甲基化谱可识别临床变量存在差异的亚组。

研究设计与样本

  • 回顾性研究,纳入本院2010年至2023年接受脊髓膜瘤切除的患者。
  • 共切除65例脊髓膜瘤,来自53例患者,中位影像学随访34个月。

主要发现

  • 53例患者中46例(87%)为女性,手术时中位年龄65岁,中位肿瘤直径1.9 cm。
  • 5年无进展生存率为90%,次全切除与复发或进展相关(p=.017)。
  • 脊髓膜瘤聚类为高甲基化、中甲基化和低甲基化亚组。
  • 高甲基化亚组肿瘤与更高WHO级别相关(p=.046),并与更高风险组织学亚型相关(p<.001)。
  • 低甲基化亚组肿瘤最不可能出现22q染色体拷贝数缺失(p<.0001)。

关键数值与推荐

  • 按先前开发的颅内脑膜瘤分类器归类为免疫富集的脊髓膜瘤,并未显示白细胞分数升高或免疫富集肿瘤通常低甲基化基因的低甲基化。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The objective of our study was to analyze methylomic and clinical features of a cohort of spinal meningiomas (SMs) resected at our institution. METHODS: This is a retrospective study of patients undergoing SM resection at our institution between 2010 and 2023. Clinical and radiographic characteristics were reviewed and analyzed with standard statistical methods. A Partitioning Around Medoids approach was used to cluster SMs with methylation data in a combined cohort from our institution and a publicly available dataset by methylation profiles. Clinical variables and pathway analyses were compared for the resulting clusters. RESULTS: Sixty-five SMs were resected in 53 patients with median radiographic follow-up of 34 months. Forty-six (87%) patients were female. The median age at surgery was 65 years and median tumor diameter was 1.9 cm. The five-year progression-free survival rate was 90%, with subtotal resection being associated with recurrence or progression (p = .017). SMs clustered into hypermethylation, intermediate methylation, and hypomethylation subgroups. Tumors in the hypermethylated subgroup were associated with higher WHO grade (p = .046) and higher risk histological subtypes (p <.001), while tumors in the hypomethylated subgroup were least likely to present with copy-number loss in chromosome 22q (p <.0001). SMs classified as immune-enriched under a previously developed intracranial meningioma classifier did not have increased leukocyte fractions or hypomethylation of genes typically hypomethylated in immune-enriched tumors. CONCLUSION: SMs are more benign than their intracranial counterparts, and gross-total resection results in long term PFS. Methylation profiling identifies subgroups with differences in clinical variables.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Nandoliya KR, Congivaram H, Youngblood MW, et al. Clinical and methylomic features of spinal meningiomas. J Neurooncol. 2024. PMID: 39254813. doi:10.1007/s11060-024-04736-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。